Precipio (PRPO) Stock Price, News & Analysis

Company Overview

Precipio, Inc. (NASDAQ: PRPO) is a biotechnology and medical diagnostics company focused on improving the diagnosis of cancer and other complex diseases. The company combines specialized pathology expertise with laboratory testing and diagnostic technologies intended to help physicians identify disease accurately and support treatment decisions.

Precipio provides clinical laboratory services in areas including hematopathology, cytogenetics and molecular diagnostics. Its work is particularly focused on blood cancers and other hematologic disorders, where accurate classification can be challenging. The company’s services are designed for hospitals, laboratories, physicians and other healthcare providers.

In addition to its laboratory operations, Precipio develops diagnostic products for use in hematology and oncology. Its product portfolio has included HemeScreen, a molecular testing platform designed to detect genetic alterations associated with hematologic malignancies, and IV-Cell, a cell-culture product intended to improve the quality of chromosome analysis. Precipio is headquartered in New Haven, Connecticut, and serves healthcare customers through its diagnostic testing and laboratory offerings.

Key Stats

• Today's Range: $18.48 to $20.24
• 50-Day Range: $17.79 to $29.29
• 52-Week Range: $17.79 to $33.63
• Volume: 17,956 shs
• Average Volume: 36,416 shs
• Market Capitalization: $33.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Precipio Stock Analysis - MarketRank™

Precipio scored higher than 14% of companies evaluated by MarketBeat, and ranked 824th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Precipio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Precipio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Precipio is -29.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precipio is -29.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precipio has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.94% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently decreased by 14.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precipio does not currently pay a dividend.

Dividend Growth

Precipio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Precipio has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

Search Interest

2 people have searched for PRPO on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Precipio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.60% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

10.45% of the stock of Precipio is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/05/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:PRPO
• CIK: 1043961
• Web: www.precipiodx.com
• Phone: (203) 787-7888
• Fax: 402-452-5401
• Employees: 71
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$360 thousand
• Net Margins: -4.47%
• Pretax Margin: -4.47%
• Return on Equity: -8.49%
• Return on Assets: -5.75%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 1.77
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $24.05 million
• Price / Sales: 1.38
• Cash Flow: $0.75 per share
• Price / Cash Flow: 24.63
• Book Value: $8.31 per share
• Price / Book: 2.24

Miscellaneous

• Outstanding Shares: 1,790,000
• Free Float: 1,493,000
• Market Cap: $33.28 million
• Optionable: No Data
• Beta: 1.45